Neuroprotection & Brain Recovery Peptide Stack 2026: Semax, Dihexa, P21 & NAD+ Research Protocol

# Neuroprotection & Brain Recovery Peptide Stack 2026: Semax, Dihexa, P21 & NAD+ Research Protocol

> Research Disclaimer: This information is for research purposes only. The compounds described here are research chemicals not approved for therapeutic use in humans outside of licensed clinical settings. This is not medical advice. Always consult qualified professionals before any research use.

Overview

The brain's capacity for recovery after injury, disease, or chronic stress depends on a cascade of interconnected processes: neurotrophic factor signaling (BDNF, NGF, HGF), synaptic plasticity mechanisms (long-term potentiation and dendritic spine dynamics), neuroinflammation resolution, and the metabolic substrate supply to support neural tissue repair. Targeting any single node in this cascade typically produces limited outcomes in research models.

This neuroprotection research stack combines four compounds with distinct, complementary mechanisms:

• •Semax — ACTH analog that drives BDNF synthesis and neuroprotection through cortical pathways
• •Dihexa — HGF/MET receptor agonist that potently induces synaptogenesis and synaptic strengthening
• •P21 — CNTF-derived neuropeptide that activates STAT3/JAK signaling for neurogenesis and synaptic plasticity
• •NAD+ (and its precursors/analogs) — essential metabolic cofactor for neural bioenergetics, sirtuin activation, and PARP-mediated DNA repair in neurons

Together, these compounds address neurotrophic signaling, structural synaptic plasticity, and the metabolic substrate demands of neural tissue repair — a comprehensive approach to brain recovery research.

Why Stack These Peptides? Mechanistic Rationale

Brain recovery — whether from acute injury, chronic neurodegenerative stress, or functional decline — requires simultaneously addressing multiple failure modes:

Neurotrophic factor depletion (targeted by Semax and Dihexa): BDNF, NGF, and HGF decline in the injured or aging brain. Without sufficient neurotrophic support, synaptic connections atrophy, neurons become vulnerable to excitotoxicity, and neurogenesis in the hippocampus diminishes. Both Semax and Dihexa drive neurotrophic signaling, but through entirely different receptor systems — Semax via ACTH-mediated transcriptional upregulation of BDNF, Dihexa via direct HGF/MET receptor agonism.

Synaptic plasticity deficits (targeted by Dihexa and P21): Memory formation and cognitive recovery depend on structural changes at synapses — formation of new dendritic spines, strengthening of existing synaptic connections, and long-term potentiation (LTP). Dihexa is documented to induce dendritic spine formation with potency 1,000× greater than BDNF in some model systems. P21 activates STAT3, a transcription factor that drives expression of plasticity-related genes.

Neural metabolic failure (targeted by NAD+): Injured neurons require massive amounts of ATP and NAD+ for DNA repair (PARP activity), mitochondrial function, and sirtuin-mediated stress resistance. NAD+ depletion is an early consequence of neural injury and a driver of neurodegeneration. Supporting NAD+ levels is prerequisite for other neuroprotective strategies to function.

The four compounds thus form a logical hierarchy: NAD+ provides the metabolic foundation; Semax and Dihexa restore neurotrophic signaling; P21 drives structural synaptic plasticity on top of this restored signal environment.

Compound Profiles

Semax — ACTH(4-10)-Pro-Gly-Pro

Molecular weight: 813.9 Da

Structure: Met-Glu-His-Phe-Pro-Gly-Pro (7 amino acids; modified ACTH fragment)

Primary mechanisms: BDNF upregulation, ACTH receptor partial agonism, serotonergic/dopaminergic modulation

Administration: Intranasal (primary research route); subcutaneous also studied

Semax was developed in Russia by the Institute of Molecular Genetics of the Russian Academy of Sciences as a cognitive-enhancing and neuroprotective peptide based on the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro extension that extends biological activity:

BDNF upregulation mechanism: Semax's primary documented mechanism in neuroprotection research is upregulation of BDNF (brain-derived neurotrophic factor) and its receptor TrkB in cortical tissue. BDNF is the most important neurotrophic factor for adult cortical and hippocampal neuron survival and plasticity. Research from multiple Russian and international groups has documented 50–200% increases in BDNF mRNA and protein in cortical tissue after Semax administration in animal models.

Stroke and ischemia research: Semax was approved in Russia for stroke recovery (Semax 1%) and has been studied extensively in models of middle cerebral artery occlusion (MCAO). In these models, Semax reduces infarct volume, preserves neurological function, and accelerates behavioral recovery. These effects are associated with upregulation of BDNF, VEGF, and anti-apoptotic factors.

Cognitive and nootropic research: Semax demonstrates cognitive-enhancing effects in animal models of memory and attention, including water maze performance improvements. Human studies from Russian clinical trials (registered in ClinicalTrials.ru) have reported improved attention and working memory, though these studies have not been replicated in large Western RCTs.

Serotonin and dopamine interactions: Semax modulates serotonergic and dopaminergic neurotransmission in limbic areas, relevant to mood, motivation, and the neurochemical environment that supports neuroplasticity.

Research parameters: Intranasal doses in research protocols range from 25–400 mcg per administration; subcutaneous doses in animal models vary. Approved Russian clinical doses: Semax 0.1% at 30 mcg/kg daily for acute stroke.

See full research profile: Semax

---

Dihexa — N-Hexanoic-Tyr-Ile-Ahx-6 (HGF/MET Agonist)

Molecular weight: 477.6 Da

Structure: N-terminal hexanoic acid modified angiotensin IV analog

Primary mechanism: HGF/c-Met receptor agonism → synaptogenesis, LTP enhancement

Development: Originally developed at Washington State University (Harding JW, McCoy AT, et al.)

Dihexa is a small-molecule peptidomimetic developed from the angiotensin IV analog Nle1-angiotensin IV at Washington State University. It was designed to penetrate the blood-brain barrier and activate the hepatocyte growth factor (HGF) / c-Met signaling axis in the brain:

HGF/c-Met in the brain: HGF is expressed throughout the brain and acts through the c-Met receptor tyrosine kinase to promote neuronal survival, axonal outgrowth, and synaptogenesis. HGF/c-Met signaling is one of the most potent pro-synaptogenic pathways in the adult brain. In Alzheimer's disease research models, HGF signaling is impaired, and restoring it improves learning and memory.

Synaptogenesis and dendritic spine formation: McCoy et al. demonstrated that Dihexa induces dendritic spine formation and new synapse creation in hippocampal neurons with potency reportedly 7 orders of magnitude greater than BDNF in some models. This makes Dihexa one of the most synaptogenic compounds identified in preclinical research.

LTP enhancement: Dihexa enhances long-term potentiation (LTP) in hippocampal slices — a cellular model of memory consolidation. Enhanced LTP means synapses are more easily strengthened, which is the fundamental mechanism underlying learning and memory.

Cognitive research applications: In aged rats with memory deficits, systemic Dihexa administration significantly improved performance in spatial memory tasks (Morris water maze, radial arm maze) compared to vehicle controls. These effects were dependent on c-Met signaling, as co-administration of a c-Met inhibitor blocked Dihexa's cognitive effects.

Blood-brain barrier penetration: Unlike many larger peptides, Dihexa is lipophilic enough to cross the blood-brain barrier after oral or subcutaneous administration — a critical feature for CNS research applications.

Research parameters: Animal studies have used 1–10 mg/kg orally or subcutaneously. Transdermal formulations have also been studied.

See full research profile: Dihexa

---

P21 — CNTF-Derived Neuropeptide

Molecular weight: ~2,200 Da (21 amino acids)

Origin: Derived from the binding domain of CNTF (ciliary neurotrophic factor)

Primary mechanisms: STAT3 activation, hippocampal neurogenesis, LTP, cognitive enhancement

P21 is a synthetic peptide derived from the receptor-binding domain of ciliary neurotrophic factor (CNTF). CNTF is a potent neurotrophic factor that promotes the survival of motor neurons, sensory neurons, and hippocampal neurons — but full CNTF protein has unfavorable pharmacokinetics and significant systemic side effects. P21 was designed to capture CNTF's neuroprotective and neurogenic benefits in a smaller, more tractable peptide:

STAT3 signaling: P21 activates STAT3 (Signal Transducer and Activator of Transcription 3) through the CNTF receptor complex, driving expression of neurogenesis and synaptic plasticity genes. STAT3 in neurons regulates expression of neurotrophin receptors, anti-apoptotic factors, and plasticity-related proteins including Arc and Homer.

Hippocampal neurogenesis: Research using BrdU labeling in animal models has shown that P21 administration increases the proliferation and survival of new neurons in the hippocampal dentate gyrus — a region critical for memory formation. Neurogenesis in the adult hippocampus is one of the few confirmed examples of new neuron creation in adult mammals and is associated with antidepressant effects and improved spatial memory.

Amyloid-β research: In Alzheimer's disease model research, P21 has been studied for its ability to reduce amyloid-β burden and improve cognitive performance. Some research suggests P21 may reduce the neuroinflammatory environment that accelerates Aβ plaque accumulation, though this area requires further investigation.

Complementarity with Dihexa: While Dihexa drives HGF/c-Met-mediated synaptogenesis, P21 drives CNTF/STAT3-mediated neurogenesis and plasticity gene expression. These are non-overlapping pathways that together create both new neurons (P21) and strengthen connections between existing neurons (Dihexa) — a complementary approach to structural brain recovery.

Research parameters: Preclinical studies have used intranasal and systemic routes; doses have varied across research groups.

See full research profile: P21 Neuropeptide

---

NAD+ (Nicotinamide Adenine Dinucleotide)

Molecular weight: 663.4 Da

Forms researched: NAD+ directly (IV), NMN (precursor), NR (precursor), NADH

Primary mechanisms: Sirtuin co-substrate, PARP substrate, Complex I cofactor, gene regulation

NAD+ is not a peptide but a nucleotide coenzyme that is nevertheless increasingly studied as a research compound due to its fundamental role in cellular energy metabolism and DNA repair. Its relevance to neuroprotection is profound:

NAD+ and neural injury: After brain injury, PARP-1 (poly-ADP ribose polymerase) is massively activated to repair DNA strand breaks — consuming NAD+ rapidly. This NAD+ depletion impairs mitochondrial function, ATP production, and sirtuin activity, creating a metabolic crisis that exacerbates neuronal death. Research shows that maintaining or restoring NAD+ levels after neural injury significantly reduces cell death and improves functional recovery.

Sirtuin activation and neuroprotection: NAD+ is the obligate co-substrate for sirtuin deacylases (SIRT1-7), which regulate neuronal stress resistance, mitochondrial biogenesis (SIRT1, SIRT3), and autophagy. SIRT1 in particular plays a critical role in promoting neuronal survival and synaptic plasticity through deacetylation of p53, NF-κB, and PGC-1α. High NAD+ levels are necessary for robust sirtuin activity.

Mitochondrial bioenergetics: Complex I of the mitochondrial electron transport chain uses NADH as its electron donor. In the brain — which consumes approximately 20% of the body's energy despite being only 2% of body weight — efficient mitochondrial function is critical. NAD+ supplementation improves mitochondrial coupling efficiency in aged neural tissue and in models of neurodegeneration.

NAD+ decline with aging and injury: NAD+ levels decline approximately 50% from young to old age due to increased PARP activity, declining biosynthesis, and increased CD38 expression. This decline correlates with mitochondrial dysfunction and cognitive decline. Restoring NAD+ via precursors (NMN, NR) or direct supplementation is the subject of extensive aging and neuroscience research.

Research parameters: IV NAD+: research infusions have studied 0.5–1 g over several hours. Oral NMN: 250–1,000 mg/day in human research (NMN crosses gut readily). Oral NR: 300–1,000 mg/day in published human trials.

See full research profile: NAD+ Research Profile

Stack Protocol

Dosing Windows & Sequencing

Morning (upon waking, fasted):

• •Semax (intranasal): Morning administration capitalizes on cortisol peak (which amplifies ACTH-pathway signaling) and sets the neurotrophic tone for the day. Allow 10–15 min post-administration before other compounds.
• •NAD+ (oral precursor or IV): Morning NAD+ dosing provides metabolic substrate during the day's peak cognitive activity. Oral NMN or NR taken with or without food.

Midday (with or just after lunch):

• •Dihexa (oral or subcutaneous): Taken approximately 4–6 hours after Semax to allow Semax-induced BDNF upregulation to prime the synaptic environment before Dihexa drives synaptogenesis. The two compounds' neurotrophic effects may synergize when sequenced this way.

Evening (1–2 hours before sleep):

• •P21 (intranasal or subcutaneous): CNTF/STAT3-mediated neurogenesis occurs during sleep-stage recovery. Evening P21 aligns with peak hippocampal neurogenesis activity during slow-wave and REM sleep.

Reconstitution Notes

Semax:

• •Supplied as lyophilized powder; reconstitute with sterile saline or water to 0.1% or 1% concentration for intranasal use
• •Intranasal: ~0.01–0.1 mL per nostril per administration
• •Store reconstituted at 4°C; stable for 4 weeks; lyophilized indefinitely at -20°C

Dihexa:

• •Reconstitute lyophilized Dihexa with DMSO:water mixtures (50:50) for subcutaneous research or with sterile saline for systemic administration
• •Oral: some protocols dissolve in corn oil or vegetable glycerin
• •Store at -20°C (lyophilized); 4°C (reconstituted, use within 2 weeks)

P21:

• •Reconstitute with sterile BAC water to 1–5 mg/mL
• •Intranasal: dilute to appropriate concentration in sterile saline; some researchers use DMSO 5% carrier
• •Store at -20°C; reconstituted at 4°C for up to 3 weeks

NAD+ (IV):

• •Dilute in 250–500 mL sterile NS or D5W for slow IV infusion
• •Prepare fresh; do not store reconstituted IV NAD+
• •NMN/NR oral capsules: room temperature storage per manufacturer

Storage Summary

Research Evidence Summary

The neuroprotection evidence base for this stack:

• •Semax: Published in peer-reviewed Russian and international journals; approved in Russia for stroke. BDNF upregulation mechanism is well-characterized. Awaits large Western RCT validation.
• •Dihexa: Published by multiple research groups; HGF/c-Met synaptogenesis mechanism is well-established. Cognitive enhancement in aged rodent models is reproducible.
• •P21: CNTF-derived neurogenesis research is emerging; multiple preclinical studies support STAT3-mediated neurogenic effects.
• •NAD+: Extensive literature on NAD+ in neural bioenergetics, PARP biology, and sirtuin activation. Human NAD+ precursor trials (NMN, NR) have demonstrated safety and NAD+ repletion efficacy.

No published trial has combined all four compounds. The mechanistic rationale for the combination is well-grounded in neuroscience.

Frequently Asked Questions

Q: How does Semax differ from other ACTH analogs in research?

A: Semax's Pro-Gly-Pro C-terminal extension distinguishes it from pure ACTH(4-10) fragments, conferring greater CNS stability and prolonged biological activity. It also has documented direct effects on BDNF that are not shared by all ACTH analogs.

Q: Is Dihexa available commercially for research?

A: Dihexa is synthesized by several research peptide suppliers. Its unique HGF/MET mechanism makes it distinct from other nootropic peptides. Verify purity via HPLC certificate before research use.

Q: Can NAD+ be taken orally instead of IV?

A: Oral NAD+ precursors (NMN, NR) significantly increase plasma and tissue NAD+ levels in research subjects. Direct oral NAD+ is less bioavailable than precursors. IV NAD+ achieves higher peak plasma levels but requires clinical administration. For most research contexts, oral NMN or NR is preferred.

Q: Does the neuroprotection stack help with Alzheimer's disease research?

A: Each compound in this stack has been studied in Alzheimer's-relevant models: Semax in ischemia/neurodegeneration models, Dihexa in Alzheimer's model rodents (improved memory), P21 in amyloid models, and NAD+ in neurodegeneration models. These are preclinical findings that require human trial validation.

Where to Source These Peptides

Compare verified suppliers for each compound in this stack:

• •Compare Semax suppliers
• •Compare Dihexa suppliers
• •Compare P21 suppliers
• •Compare NAD+ and NMN suppliers

For research purposes only. Verify compound purity via third-party Certificate of Analysis before any research use.